The US drugs maker is offering its stockholders the chance to swap at a discount into shares of its publicly traded subsidiary Mead Johnson. That would improve Bristol’s earnings per share - which should come in handy with as much as 30% of its sales at risk as patents expire.Sign up to read the rest of this subscriber-only content, or if you are already a member please sign in here.
Forgotten your password? Get a password reminder.
This Views Flash will shortly be followed by a Considered View